Welcome to our dedicated page for CERo Therapeutics news (Ticker: CERO), a resource for investors and traders seeking the latest updates and insights on CERo Therapeutics stock.
CERo Therapeutics Holdings, Inc. develops cellular immunotherapy candidates for cancer using engineered T cells that employ phagocytic mechanisms. Company news centers on its CER-T platform, the lead product candidate CER-1236, and clinical updates from the CERTAIN-T Phase 1 trial in hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis.
Recurring updates also address safety monitoring, pharmacokinetic and pharmacodynamic observations, dose-escalation cohorts, scientific presentations, board composition, financing activity, and trading or listing-status developments for CERO common stock and warrants.
CERo Therapeutics (OTCQB:CERO) completed the second ascending-dose cohort in its Phase 1 CERTAIN-T trial of CER-1236 for hematologic malignancies. Three patients received 4 × 10⁶ cells/kg with no dose-limiting toxicities, supporting escalation to 1 × 10⁷ cells/kg.
The trial has now treated six patients and will expand to include myelodysplastic syndrome and myelofibrosis patients.
CERo Therapeutics (OTCQB: CERO) dosed the third patient in Cohort 2 (sixth patient overall) of the Phase 1 CER-1236 trial in hematologic malignancies on April 14, 2026. The study was expanded to include transfusion-dependent and high-risk MDS and post-JAK inhibitor myelofibrosis.
Key clinical observations include no reported CRS or ICANS, no dose-limiting toxicities in the 28-day window, observed in vivo cell expansion (peaks days 10–14), and one patient achieving 72 days of platelet transfusion independence after repeated infusions.
CERo Therapeutics (OTCQB: CERO) dosed the second patient in Cohort 2 (fifth overall) of its Phase 1 CER-1236 trial on March 30, 2026, advancing safety, PK/PD and activity monitoring in AML with planned expansion into MDS and MF.
The company reported no CRS or ICANS, no dose‑limiting toxicities in the 28‑day window, in vivo T cell expansion peaking days 10–14, and a single patient with 72 days of platelet transfusion independence; enrollment was amended to include TD‑MDS, HR‑MDS, and post‑JAK‑inhibitor MF.
CERo Therapeutics (OTCQB: CERO) provided a shareholder update on March 11, 2026 describing clinical, financing, governance, and strategic progress. Key points: early clinical activity for lead candidate CER-1236 (20–70x cell expansion; one MDS patient with >56-day platelet transfusion independence), convertible debt funding to sustain operations, engagement of an investment bank to pursue a Nasdaq relisting, and the appointment of Eric Francois to the board.
CERo Therapeutics (OTCQB: CERO) appointed industry veteran Eric Francois to its Board of Directors effective Feb 17, 2026. Francois brings over 25 years in life sciences finance, including 18 years as a senior banker and prior service as CFO who helped raise over $300M.
The company highlighted his strengths in capital raising, M&A and business development to support CERo's cellular immunotherapy programs and ongoing human clinical trial.
CERo Therapeutics (OTCQB:CERO) will present interim Phase 1 CERTAIN-T data at ASTCT/CIBMTR on February 5, 2026. Key findings include approximately 20–70-fold in vivo cell expansion peaking days 7–14, no dose-limiting toxicities in first four patients, and an index AML/MDS patient achieving platelet transfusion independence >56 days. The trial has been amended to include transfusion-dependent MDS, high-risk MDS, and post-JAK-inhibitor myelofibrosis; cohort 2 enrollment is underway.
CERo Therapeutics (OTCQB: CERO) provided a Phase 1 CertainT-1 clinical update for CER-1236 in AML on January 7, 2026.
Key points: investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events to date; a patient with MDS that progressed to AML had a 61-day platelet transfusion–free interval, exceeding an 8-week benchmark; transfusion independence ended after a later round of lymphodepleting chemotherapy plus CER-1236. The company filed an amendment with the FDA to add advanced MDS and myelofibrosis cohorts and will host an analyst call on Jan 7, 2026 at 5:00 PM ET.
CERo Therapeutics (OTCQB: CERO) provided a Phase 1 CertainT-1 clinical update for CER-1236 in acute myeloid leukemia (AML) on December 17, 2025. The company reported completion of the dose‑limiting toxicity (DLT) observation period for Cohort 1.
The first patient in Cohort 2 was dosed at 4e6 cells/kg (four times the Cohort 1 dose of 1e6 cells/kg) and completed the DLT observation period. A second patient in Cohort 1 received a fourth additional dose and remains on study. The trial is a first‑in‑human, multi‑center, open‑label Phase 1/1b study evaluating safety and preliminary efficacy with primary endpoints including AEs, SAEs, DLTs, ORR, CR, cCR, and MRD; PK is a secondary measure.
CERo Therapeutics (OTCQB: CERO) announced its shares will begin trading on the OTCQB market under ticker CERO effective December 2, 2025 at 8:00 AM ET.
No investor action is required. The company said it is evaluating additional up‑list options, including a potential listing on a major exchange to improve liquidity and investor accessibility. Management reiterated focus on advancing its Phase 1 trial of CER‑1236 for AML, noting the starting dosage in the current cohort was increased significantly versus the prior cohort.
CERo Therapeutics (OTC PINK: CERO) initiated the second cohort of its first-in-human Phase 1/1b trial of CER-1236 in acute myeloid leukemia on Nov 5, 2025. The first patient in cohort 2 received an initial dose equal to twice the cohort‑1 starting dose and a second identical dose 48 hours later. Investigators reported no dose‑limiting toxicities to date, supporting escalation. The open‑label, multi‑center study uses dose escalation to find a Phase 2 dose and an expansion phase to assess safety and preliminary efficacy with endpoints including AEs/SAEs, DLTs, ORR, CR, cCR, MRD and PK.
The company noted observed cell expansion and continues dosing while evaluating options to list the stock on a public exchange.